Royalty Pharma leads in biopharma royalties, offering stable returns and growth potential.

Royalty Pharma plc is the global leader in acquiring biopharmaceutical royalties, focusing on de-risked, post-proof-of-concept assets. The company offers investors exposure to blockbuster therapies with attractive risk-adjusted returns, including around 15% return on invested capital and near 21% equity returns. Its business model is defensive and uncorrelated with macroeconomic trends, benefiting from scale, high operating margins, and expert capital allocation. Management prioritizes high-return investments or share buybacks, making Royalty Pharma a strong choice for portfolio diversification and standalone growth.

Royalty Pharma trades with a market cap of $29.55 billion and a dividend yield of 1.42% as of Nov 05, 2026 05:21 WIB on Pluang. The stock price is $67.77, showing a 2.06% increase in one day, while the platform records a volume of 3,149,198 shares traded. Despite the news highlighting strong returns and a defensive business model, Pluang order activity currently shows 100% sell interest.